Pfizer
New research gives a boost to the UK government's decision to delay the second dose of the Pfizer/BioNTech jab, but experts still urge caution.
Here’s a look at how the global vaccination programme is progressing – and why it matters just as much how other countries are faring as your own.
A bust-up between the European Union and the pharma giant has led to supply worries.
The BMA has warned there is no guarantee of the UK having enough Pfizer/BioNTech jabs in 12 weeks to deliver second doses.
One in eight adults aged 16-29 reported vaccine hesitancy in the latest data period, ONS has revealed.
The study, though not peer reviewed, is encouraging news in the fight against coronavirus.
Mark Drakeford defended delaying the roll out, saying using all of its stock would mean "all our vaccinators standing around with nothing to do".
Six European leaders, also affected by the upcoming delay, have described the situation as "unacceptable".
Trials are underway to explore whether vaccines can be mixed. Here's what you need to know.
The government issued guidance on New Year's Eve saying it was "reasonable" for two different vaccines to be given to the same patient if one type was unavailable.